CPDR Patient Education Program
Industry-Sponsored Clinical Trials and Projects
The CRC maintains a comprehensive portfolio of both investigator-initiated and industry sponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, are investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. All trials and projects are carried out with full approval of the respective IRBs.
CPDR Open Clinical Trials
ProstAtak TrialA randomized trial of ProstAtak in combination with standard external beam radiation therapy with or without androgen deprivation therapy is in men with intermediate to high risk localized prostate cancer. ProstAtak is an investigational product that is meant to kill tumor cells and elicit an anti-tumor vaccine effect. In a Phase II clinical trial of ProstAtak given with radiation, prostate cancer recurrence was three-fold lower than typically seen with radiation alone. The purpose of this Phase III trial is to definitively determine if ProstAtak reduces prostate cancer recurrence
BAYER - RADIUM 223A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride (radium 223 dichloride is FDA approved drug that targets prostate cancer in the bones), in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer
AMOR3-SVA phase 3, randomized, open-label, multi-center, controlled study of Galeterone compared to Enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) with metastatic (M1) castrate resistant prostate cancer (CRPC). Galeterone is a selective, multi-targeted, small molecule drug for the treatment of castrate resistant prostate cancer
CONTACT Information: Judith A. Travis, RN, Walter Reed National Military Medical Center, Center for Prostate Disease Research, America Building 19, Room 3225 on the 3rd floor.
301-319-2927 or Judith.firstname.lastname@example.org
2018 AACR Annual Meeting
Chicago, Illinois April 14-18, 2018
The 2018 AACR Annual Meeting gathered this year at McCormick Place, Chicago, Illinois from April 14 to 18 under the theme of Driving Innovative Cancer Science to Patient Care. The Center for Prostate Disease Research (CPDR) multi-disciplinary team - together with collaborators – delivered one podium presentation and 12 poster presentations. The team was co-led by Dr. Shiv Srivastava, CPDR Co-Director and Professor, and Dr. Albert Dobi, Associate Director, CPDR and Research Assistant Professor, of the Department of Surgery, USU and WRNMMC.
Read the March 2019 CPDR E-Newsletter
ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development
Scientific Reports | 7: 1109 | DOI:10.1038/s41598-017-01187-4
Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells
Mol Cancer Res. 2017 Oct;15(10):1308-1317. doi: 10.1158/1541-7786.MCR-17-0058. Epub 2017 Jun 12.
Ethnicity and ERG Frequency in Prostate Cancer
Nat Rev Urol. 2017 Sep 5. doi: 10.1038/nrurol.2017.140. [Epub ahead of print]